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Background: Although systolic blood pressure (SBP) in heart failure patients has shown to be a good predictor of mortality in HF patients, the 
underlying variables as to why higher SBP gives a better prognosis has not been well studied.
Methods: Cohort study using data from Clinical Information Manager for Heart Failure (CIM-HF) registry for chronic HF patients from 2006 to 2009. 
We have reviewed a total of 384 patients followed for 6 months or longer. Patients were divided into by SBP at initial presentation (<120 mmHg = 
Normal SBP; > 120 mmHg = High SBP). There were a total of 313 patients in the normal BP group and 71in the high BP group. Of those with left 
ventricular function assessed, 25% and 39% had preserved left ventricular function, respectively.
Results: A greater percentage of patients in the high SBP group reached target and maximum dosages of ACE and/or ARB as well as beta blockers. 
However, of those who reached the maximum dosage of ACE/ARB and BB, the same number of visits (7.1 vs. 6.0 (mean); 4 vs 4 (median), p<0.13 for 
ACE/ARB and 7.5 vs. 6.4 (mean); 6 vs 5 (median), p<0.08 for the beta blocker group), respectively (P<NS for overall difference).
Conclusion: Heart failure patients with higher SBP may very likely have a favorable prognosis due to their ability to achieve target and maximum 
dosages of ACE/ARB and beta blockers. These findings may have important therapeutic implications because characteristics and outcomes differ 
greatly among patients with heart failure with varying SBP. 
